Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 11129 - 11136 of 12008 results
OIG Report Critical of P&T Committee Oversight
March 11, 2013| Blog| Viewpoint
FTC Staff Report Shines a Light on the Treacherous Road Ahead for Mobile Payments
March 11, 2013| Blog| Viewpoint
USCIS Revises Form I-9 (Employment Eligibility Verification Form)
March 9, 2013| Blog| Viewpoint
Detailed Analysis of the Final Rule Implementing the Physician Payments Sunshine Act
March 8, 2013| Blog| Viewpoint
USCIS Revises Form I-9 (Employment Eligibility Verification Form)
March 8, 2013| Alert| Viewpoint
An Insider’s Guide to Evading Absolute Priority? Seventh Circuit: New value competition requirements apply to insiders
March 7, 2013| Advisory| Viewpoint
Future Energy Startup-Investor Pitch in collaboration with the MIT Clean Energy Prize: April 4th (applications due March 6)
March 5, 2013| Blog| Viewpoint
April 1 2013 Deadline for Filing H-1B Visa Petitions Approaches
March 1, 2013| Alert| Viewpoint
News & Press Releases
Mintz advised The Eagle Leasing Company, a leading provider of portable storage containers, ground level offices, semi-trailers, and mobile office solutions, in its acquisition by Rent-A-Container (RAC), a portfolio company of Kinderhook Industries, LLC.
Mintz’s Life Sciences practice has been shortlisted in multiple categories for the 2025 LMG Life Sciences Americas Awards. The winners will be announced at an awards ceremony in New York on September 4. In the United States, Mintz was shortlisted in the “Venture Capital Firm of the Year” category. In Canada, Mintz was shortlisted in the “Financial & Corporate Firm of the Year” and “Patent Strategy Firm of the Year” categories.
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|